FDA Approves Extended Five-Year Use of NEXPLANON Contraceptive Implant
核心洞察
The FDA has approved Organon's supplemental New Drug Application extending NEXPLANON contraceptive implant use from three to five years, with clinical trials showing zero pregnancies during the extended period.
The approval includes comprehensive data on women with varying BMI values, including 38.1% with BMI ≥30 kg/m², demonstrating efficacy across diverse patient populations.
A new Risk Evaluation and Mitigation Strategy (REMS) program will be implemented starting February 2026 to ensure proper provider training for insertion and removal procedures.
Organon announced that the US Food and Drug Administration has approved a supplemental New Drug Application for NEXPLANON (etonogestrel implant), extending the contraceptive device's approved duration of use from three to five years. The approval represents a significant advancement in long-acting reversible contraception options for women of reproductive potential.
Clinical Trial Results Demonstrate Sustained Efficacy
The extended-use approval is supported by a multicenter, single-arm, open-label study (NCT04626596) that evaluated 399 women who had been using NEXPLANON for 36 months at enrollment. During the clinical trial assessing contraceptive efficacy and safety for years four and five, no pregnancies were reported, resulting in a Pearl Index of 0.0 (95% CI: 0.00, 0.69) pregnancies per 100 women-years of use.
The study population had a mean age of 27 years, ranging from 18 to 35 years. Participants demonstrated significant demographic diversity: 74.2% White, 16.8% Black/African American, 3.8% Asian, 1.3% American Indian or Alaska Native, 0.5% Native Hawaiian or Other Pacific Islander, and 3.5% multiple or missing races.
Efficacy Across Diverse BMI Ranges
A notable aspect of the trial was its inclusion of women across a broad range of body mass index values. The study enrolled participants with BMI values ranging from 17.2 to 64.3 kg/m², with a mean BMI of 29.4 kg/m². Significantly, 152 participants (38.1%) had a BMI ≥30 kg/m², including 40 participants (10.0%) with a BMI ≥40 kg/m².
"The sNDA approval of an extended duration up to five years, along with data about the use of NEXPLANON in women with varying BMIs, including women with overweight or obesity (搜索), is a testament to Organon's commitment to inclusive and comprehensive women's healthcare," said Juan Camilo Arjona Ferreira, MD, Organon's Head of Research and Development and Chief Medical Officer.
Enhanced Safety Measures Through REMS Program
The FDA approval includes implementation of a new Risk Evaluation and Mitigation Strategy (REMS) program to mitigate complications due to improper insertion and removal. The NEXPLANON REMS program will be available starting February 23, 2026, with providers having six months to enroll to maintain access to the contraceptive implant.
The REMS program requires healthcare providers to complete certification training on proper insertion and removal procedures before first use. Pharmacies must also be certified and can only dispense NEXPLANON to certified healthcare providers. Wholesalers and distributors must register with the program and distribute only to certified entities.
"The REMS program builds on existing training requirements to ensure providers maintain the highest standards for insertion and removal, reinforcing confidence and best clinical practice," said Anita Nelson, MD, Professor of Obstetrics and Gynecology at Western University of Health Sciences.
Safety Profile Remains Consistent
The extended-use trial revealed no new safety findings compared to the established three-year safety profile. In the five-year study, the most frequently reported adverse reaction exceeding 5% was intermenstrual bleeding (5.4%). Changes in menstrual bleeding patterns were the most frequently reported adverse reaction leading to discontinuation, occurring in 4.0% of participants.
This safety profile aligns with previous clinical trials where the most common adverse reactions (≥5%) included headache (24.9%), vaginitis (14.5%), weight increase (13.7%), acne (13.5%), breast pain (12.8%), abdominal pain (10.9%), and pharyngitis (10.5%).
Clinical Implications for Women's Healthcare
The extended duration approval addresses a significant need in contraceptive care by reducing the frequency of replacement procedures. NEXPLANON is indicated for prevention of pregnancy (搜索) in women of reproductive potential for up to five years, offering a highly effective long-acting reversible contraceptive option.
"The updated label for NEXPLANON reflects the diversity of patients we see every day—women throughout their reproductive ages, those seeking a long-acting option of up to five years, those who prefer birth control that goes in the arm rather than the uterus, and women across a wide range of BMIs," Nelson noted.
The approval enhances Organon's existing Clinical Training Program and controlled distribution program, which has been in place since 2006, by instituting proactive measures to certify providers in proper insertion and removal techniques.